Platform for discovering and developing first-in-class antibody medicines
AbCellera is a leading antibody discovery company using single-cell screening and AI to identify binders from immune repertoires at high speed. It excels in rapid hit identification for traditional targets and has supported multiple clinical programs through partnerships. Unlike Abalone Bio's focus on functional activation of GPCRs via massive parallel activity assays and survival-linked yeast, AbCellera prioritizes binding affinity and structural characterization with smaller functional follow-up. Its platform suits high-throughput discovery but lacks Abalone Bio's 100M-scale activity datasets for training AI on activators, making it less ideal for hard-to-drug GPCR modulation where precise function is required over inhibition.
AbCellera develops antibody-based medicines using a platform that integrates biology, computation, and engineering to advance programs from target to clinic. Its internal pipeline includes ABCL635, a first-in-class NK3R-targeted antibody in Phase 1/2 for non-hormonal treatment of menopausal vasomotor symptoms, ABCL575, an OX40L antibody in Phase 1 for atopic dermatitis with Fc-silencing and half-life extension, plus ABCL688 and ABCL386 in autoimmunity and oncology. The company has advanced 100+ programs over 14+ years with 40+ partners.
Free

Culturally responsive mental health resources and therapist directory for Black women and girls.

NYC-based online therapy with licensed therapists accepting insurance for anxiety, trauma, and life transitions.
Online therapy for teens and parents via text, phone, and video from licensed therapists.